Efficacy study of cisplatin beads
Ended Project Grant Awarded Last action
- Award ID
- R01FD007246
- Recipient
-
Royer Biomedical Inc. UEI ZXCJMRN7KYT3
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $258,213
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date
- Originally
- Funding
-
- $172,142.00 Federal
- $86,071.00 Non-federal
- Funding agency
- Center for Veterinary Medicine Food and Drug Administration, Department of Health and Human Services
- Place of performance
- Maryland, USA
Award details come from USAspending.gov.
Description
- Abstract
- Field efficacy study of cisplatin beads for the treatment of sarcoid in horses the objective of this study is to determine the efficacy of treatment for cutaneous sarcoids in horses with cisplatin impregnated, slow release beads. Ten horses, client-owned, with spontaneously developing cutaneous sarcoids of < 3 CM diameter will be utilized. Gender, age, reproductive status and breed will be documented in the study. Horses will be examined prior to bead implantation to ensure that they are systemically healthy and there are no comorbidities. This will be determined by physical examination, serum chemistry analysis, complete blood cell count, and urinalysis with GGT/creatinine ratio. On day 0, the sarcoid will be surgically excised, and the incision site will be implanted with up to 3 cisplatin- impregnated beads. The tissue removed will be stored in 10% buffered formalin and submitted for routine histopathological analysis. Horses will subsequently be monitored by routine clinical assessment as deemed appropriate by the treating clinician for the surgical site. At minimum, the surgical site will be reexamined at 10 days and 180 days, and the site documented by photograph. More frequent assessment may occur based upon clinical need. Success will be defined as no recrudescence of the sarcoid at that location within 180 days in greater than 50% of the treated horses. This success criterion is based upon the reported finding of a success rate of 30-50% of cases treated by surgical excision alone, in which "most tumors recurred within 6 months".
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $86,071 | $0 | |
| Original award | $86,071 | $86,071 |
Show all 12
Quick answers
Who received award R01FD007246?
R01FD007246 was awarded to Royer Biomedical Inc. by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on December 1, 2020.
How much is award R01FD007246 worth?
$258,213 has been obligated on R01FD007246: $172,142 in federal funding and $86,071 in non-federal funding.
Which agency awarded R01FD007246?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD007246, with funding from Center for Veterinary Medicine (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award